Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
CRDF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.01 - $6.38
Previous CloseN/A
Volume446.20K
Average Volume (3M)1.18M
Market Cap
$208.89M
Enterprise Value$149.53M
Total Cash (Recent Filing)$700.37K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 01, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding66,524,290
10 Day Avg. Volume1,183,820
30 Day Avg. Volume1,176,028
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)365.25
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit218.93
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$15.67Price Target Upside412.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Cardiff Oncology News
PremiumCompany Announcements
Cardiff Oncology’s Earnings Call: Optimism Amid Challenges
PremiumCompany Announcements
Cardiff Oncology Highlights Progress in Cancer Trials
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOnvansertib 30mg combined with standard-of-care demonstrated a 64% objective response rate, showing highly promising results in the CRDF-004 trial.
Financial OutlookThe probability of approval for onvansertib has been raised to 40%, and the 12-month price target for Cardiff Oncology shares has been increased to $17.
Market PotentialThe KRAS+ colorectal cancer market is underserved, and successful results with onvansertib could drive a paradigm shift in treatment and make Cardiff Oncology an attractive acquisition target.
Bears Say
Clinical RisksRisks include negative or poorer-than-anticipated clinical results for onvansertib in the ongoing CRDF-004 trial.
Regulatory ChallengesRisks also include delays in advancing onvansertib into pivotal clinical studies and failure to obtain onvansertib approval.
---
Ownership Overview
3.57% Insiders
4.96% Mutual Funds
22.23% Other Institutional Investors
62.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $2.01 and its highest was $6.38 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $208.89M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is May 01, 2025 which is in 29 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Feb 27, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.026.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 66,524,290 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went up 4.433%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
---
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (412.09% Upside)
$15.67 (412.09% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 42.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $36.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.59%
12-Months-Change
Fundamentals
Return on Equity
-59.51%
Trailing 12-Months
Asset Growth
19.05%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) is a clinical-stage biotechnology company focused on developing new treatment options for cancer patients. The company operates in the biotechnology and pharmaceuticals sector, specializing in precision oncology therapies. Cardiff Oncology's core product is onvansertib, a first-in-class, oral and highly selective inhibitor of the PLK1 enzyme, which is being evaluated in combination with standard-of-care therapeutics across a variety of cancer types, including colorectal cancer and pancreatic cancer.
---
CRDF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.Read More>---
CRDF Stock 12 Month Forecast
Average Price Target
$15.67
▲(412.09% Upside)
Technical Analysis
Exelixis
―
Gilead Sciences
―
Karyopharm Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering CRDF
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
+12.88%
reiterated a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +12.88% per trade.
---